

Patent
100848.213102US4

ribavirin to the patient under a protocol intended to promote the Type 1 response and suppress the Type 2 response, and adding interferon alpha to the lymphocytes.

6. A method of inhibiting a virus by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration for the purpose of increasing the Type 1 response and suppressing the Type 2 response, wherein the virus comprises Hepatitis C.
7. The method of claim 6 wherein the environment comprises a liver.
8. The method of claim 6 wherein the environment comprises hepatocytes.
9. The method of claim 6 wherein the environment comprises a liver.
10. The method of claim 6 wherein the environment comprises hepatocytes.
11. A method of inhibiting a virus by growing HCV in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin and an alpha interferon to the environment in a concentration with the expectation of increasing the Type 1 response and suppressing the Type 2 response.
12. The method of claim 11 wherein the environment is a human patient, and ribavirin is administered to the human patient at no more than 800 mg/day.
13. The method of claim 12 wherein ribavirin is administered at no more than 600 mg/day.

REMARKS

Allowable Subject Matter

Claims 2, 4, and 6-10 were deemed allowable over the prior art, but were rejected under non-statutory double patenting. The applicant already filed terminal disclaimers to overcome those rejections.